Pimobendan
Pimobendan is a cardiovascular drug commonly used to treat congestive heart failure, dilated cardiomyopathy, and chronic valvular heart disease in veterinary medicine. This compound exhibits vasodilatory and antithrombotic activities, decreasing peripheral resistance and inhibiting platelet aggregation. Pimobendan selectively inhibits cardiac phosphodiesterase III (PDE3), increasing myocardial cAMP and causing positive inotropic effects such as an increase in heart rate, left ventricle systolic pressure, and left ventricle filling pressure, and a decrease in peripheral resistance (mean arterial pressure).
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18954521
| Cas No. |
74150-27-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H18N4O2 |
| Formula Wt. |
334.37 |
| IUPAC Name |
3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one |
| Synonym |
Acardi; pimobendane |
| Solubility |
DMSO 67 mg/mL; Water <1 mg/mL; Ethanol 5 mg/mL |
| Appearance |
White to off white powder |
Shipley EA, Hogan DF, Fiakpui NN, et al. In vitro effect of pimobendan on platelet aggregation in dogs. Am J Vet Res. 2013 Mar;74(3):403-7. PMID: 23438115.
Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012 Aug;22(4):398-408. PMID: 22928748.
Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol. 1986 Jul 15;126(1-2):21-30. PMID: 2875884.
Scholz H, Meyer W. Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation. 1986 Mar;73(3 Pt 2):III99-108. PMID: 2417748.
